TGF-beta3 and cancer: a review.

[1]  Andrew V. Nguyen,et al.  Transforming growth factor beta3 induces cell death during the first stage of mammary gland involution. , 2000, Development.

[2]  R. Folberg,et al.  Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. , 2005, American journal of ophthalmology.

[3]  Shant Kumar,et al.  Plasma CD105, TGFbeta-1, TGFbeta-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia. , 2006, Anticancer research.

[4]  Joshy George,et al.  Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. , 2006, Cancer research.

[5]  M. Ferguson,et al.  Pathogenesis of cleft palate in TGF-beta3 knockout mice. , 1999, Development.

[6]  Ash A. Alizadeh,et al.  Gene Expression Signature of Fibroblast Serum Response Predicts Human Cancer Progression: Similarities between Tumors and Wounds , 2004, PLoS biology.

[7]  F. Talamantes,et al.  Short-term exposure to pregnancy levels of estrogen prevents mammary carcinogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Stähelin,et al.  TGF-beta s and TGF-beta type II receptor in human epidermis: differential expression in acute and chronic skin wounds. , 1993, The Journal of pathology.

[9]  A. Balmain,et al.  Genetic events and the role of TGFβ in epithelial tumour progression , 1999 .

[10]  J. Russo,et al.  Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. , 1980, Cancer research.

[11]  A. Halpern,et al.  Melanoma-associated expression of transforming growth factor-beta isoforms. , 1996, The American journal of pathology.

[12]  M. Sporn,et al.  Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. , 1996, Biochemistry.

[13]  R Wieser,et al.  TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. , 1999, The Journal of clinical investigation.

[14]  Mahlon D. Johnson,et al.  Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression. , 1993, The Journal of clinical investigation.

[15]  Allan Balmain,et al.  TGFβ1 Inhibits the Formation of Benign Skin Tumors, but Enhances Progression to Invasive Spindle Carcinomas in Transgenic Mice , 1996, Cell.

[16]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[17]  S. Yuspa,et al.  Induction of papillomas with a high probability of conversion to malignancy. , 1985, Carcinogenesis.

[18]  M. Kurosaka,et al.  Expression of Transforming Growth Factor β Isoforms and Their Receptors in Malignant Fibrous Histiocytoma of Soft Tissues , 2004, Clinical Cancer Research.

[19]  U. Rodeck,et al.  Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. , 1999, Cancer research.

[20]  L. Wakefield,et al.  TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. , 2003, The Journal of clinical investigation.

[21]  A. Arseniev,et al.  Sequence-specific 1H and 15N assignment and secondary structure of transforming growth factor beta3. , 2000, Journal of biomolecular NMR.

[22]  M. Ferguson,et al.  Immunohistochemical localization of growth factors in fetal wound healing. , 1991, Developmental biology.

[23]  Justis P. Ehlers,et al.  Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death , 2004, Cancer Research.

[24]  D. Fisher,et al.  SKI activates Wnt/beta-catenin signaling in human melanoma. , 2003, Cancer research.

[25]  D. Foreman,et al.  Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. , 1995, Journal of cell science.

[26]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[27]  H. Stähelin,et al.  TGF‐βS and TGF‐β type II receptor in human epidermis: Differential expression in acute and chronic skin wounds , 1993 .

[28]  R. Derynck,et al.  Human Transforming Growth Factor- β3: Recombinant Expression, Purification, and Biological Activities in Comparison with Transforming Growth Factors-β 1 and -β2 , 1989 .

[29]  K. Flanders,et al.  Transforming growth factor‐β3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma , 1997, The Prostate.

[30]  W. Grizzle,et al.  Hormone levels and mammary epithelial cell proliferation in rats treated with a regimen of estradiol and progesterone that mimics the preventive effect of pregnancy against mammary cancer. , 1997, Anticancer research.

[31]  A. Berchuck,et al.  Progestin-induced apoptosis in the Macaque ovarian epithelium: differential regulation of transforming growth factor-beta. , 2002, Journal of the National Cancer Institute.

[32]  V. Kaartinen,et al.  Tgfb1 expressed in the Tgfb3 locus partially rescues the cleft palate phenotype of Tgfb3 null mutants. , 2007, Developmental biology.

[33]  Andy J. Minn,et al.  Genes that mediate breast cancer metastasis to lung , 2005, Nature.

[34]  David Handelsman,et al.  Identification of differentially expressed genes in organ‐confined prostate cancer by gene expression array , 2001, The Prostate.

[35]  M. O’Connor-McCourt,et al.  A transforming growth factor beta (TGF-beta) receptor from human placenta exhibits a greater affinity for TGF-beta 2 than for TGF-beta 1. , 1991, Biochemistry.

[36]  J. Cheville,et al.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. , 2003, Cancer research.

[37]  E. Gelmann,et al.  Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Davies,et al.  Crystal structure of transforming growth factor-beta 2: an unusual fold for the superfamily. , 1992, Science.

[39]  K. Miyazono,et al.  Latent forms of TGF-beta: molecular structure and mechanisms of activation. , 1991, Ciba Foundation symposium.

[40]  T. Kawakami,et al.  Overexpression of transforming growth factor‐β3 immunohistochemical staining in extramammary Paget's disease, but downregulated expression in Bowen's disease , 2001, International journal of dermatology.

[41]  U. Ripamonti,et al.  Periodontal tissue regeneration by recombinant human transforming growth factor-beta 3 in Papio ursinus. , 2007, Journal of periodontal research.

[42]  Robert Brown,et al.  Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. , 2005, Carcinogenesis.

[43]  Justin P. Annes,et al.  Making sense of latent TGFβ activation , 2003, Journal of Cell Science.

[44]  M. Ferguson,et al.  The extracellular matrix of lip wounds in fetal, neonatal and adult mice. , 1991, Development.

[45]  P. Kondaiah,et al.  Differential expression of TGF beta isoforms in murine palatogenesis. , 1990, Development.

[46]  E. Canalis,et al.  Recombinant transforming growth factor type beta 3: biological activities and receptor-binding properties in isolated bone cells , 1990, Molecular and cellular biology.

[47]  C. Welsch.  Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. , 1985, Cancer research.

[48]  A. Tsamandas,et al.  TGFbeta1, TGFbeta2, and TGFbeta3 protein expression in gastric carcinomas: correlation with prognostics factors and patient survival. , 2007, The Journal of surgical research.

[49]  T. Spector,et al.  The role of serum TGF-beta isoforms as potential markers of osteoporosis. , 1999, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.

[50]  G. Proetzel,et al.  Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease , 1992, Nature.

[51]  N. Fusenig,et al.  TGF‐β isoforms are differentially expressed in increasing malignant grades of HaCaT keratinocytes, suggesting separate roles in skin carcinogenesis , 2000, The Journal of pathology.

[52]  A. Roberts,et al.  TGF-beta is a bidirectional modulator of cytokine receptor expression on murine bone marrow cells. Differential effects of TGF-beta 1 and TGF-beta 3. , 1993, Journal of immunology.

[53]  E. Castrén,et al.  Transforming growth factor-beta 1 in the rat brain: increase after injury and inhibition of astrocyte proliferation , 1992, The Journal of cell biology.

[54]  R. Derynck,et al.  Human transforming growth factor-beta 3: recombinant expression, purification, and biological activities in comparison with transforming growth factors-beta 1 and -beta 2. , 1989, Molecular endocrinology.

[55]  Shashank Deep,et al.  Crystal structure of the human TβR2 ectodomain–TGF-β3 complex , 2002, Nature Structural Biology.

[56]  G. Prud’homme.  Pathobiology of transforming growth factor β in cancer, fibrosis and immunologic disease, and therapeutic considerations , 2007, Laboratory Investigation.

[57]  J. Russo,et al.  Mammary gland neoplasia in long-term rodent studies. , 1996, Environmental health perspectives.

[58]  Pat Kumar,et al.  Role of transforming growth factor β3 in lymphatic metastasis in breast cancer , 1998 .

[59]  R. W. Padgett.  TGFβ Signaling Pathways and Human Diseases , 2004, Cancer and Metastasis Reviews.

[60]  M. Ferguson,et al.  Inhibition of TGF-beta 3 (but not TGF-beta 1 or TGF-beta 2) activity prevents normal mouse embryonic palate fusion. , 1995, The International journal of developmental biology.

[61]  J. Russo,et al.  Susceptibility of the mammary gland to carcinogenesis: I Differentiation of the mammary gland as determinant of tumor incidence and type of lesion. , 1979, The American journal of pathology.

[62]  Richard M. Jackson,et al.  Predicting protein interaction sites: binding hot-spots in protein-protein and protein-ligand interfaces , 2006, Bioinform..

[63]  L. Gold.  The role for transforming growth factor-beta (TGF-beta) in human cancer. , 1999, Critical reviews in oncogenesis.

[64]  A. Hart,et al.  Validation of 70-gene prognosis signature in node-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[65]  M. Grütter,et al.  A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions , 2008, Proceedings of the National Academy of Sciences.

[66]  H. Dvorak.  Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. , 1986, The New England journal of medicine.

[67]  I. Rayment,et al.  Crystal structure of D-ribulose 5-phosphate 3-epimerase from Synechocystis to 1.6 angstrom resolution , 2004 .

[68]  Ester Piek,et al.  Role of Transforming Growth Factor-β Signaling in Cancer , 2000 .

[69]  S. Lehnert,et al.  TGF beta in murine morphogenetic processes: the early embryo and cardiogenesis. , 1990, Development.

[70]  P. Nowell,et al.  Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. , 1994, Cancer research.

[71]  J. Russo,et al.  DNA labeling index and structure of the rat mammary gland as determinants of its susceptibility to carcinogenesis. , 1978, Journal of the National Cancer Institute.

[72]  J. Graff,et al.  Smad3 Mutant Mice Develop Metastatic Colorectal Cancer , 1998, Cell.

[73]  J. Chirgwin,et al.  Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. , 2002, The Journal of biological chemistry.

[74]  H. Auer,et al.  Tissue-Wide Expression Profiling Using cDNA Subtraction and Microarrays to Identify Tumor-Specific Genes , 2004, Cancer Research.

[75]  V. Kaartinen,et al.  Abnormal lung development and cleft palate in mice lacking TGF–β3 indicates defects of epithelial–mesenchymal interaction , 1995, Nature Genetics.

[76]  R. Demir,et al.  Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-beta's in epithelial ovarian tumors. , 2006, Histology and histopathology.

[77]  Gerard C Blobe,et al.  Role of transforming growth factor Beta in human cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  R. Derynck,et al.  TGF-β signaling in cancer – a double-edged sword , 2001 .

[79]  S. Dhanasekaran,et al.  Delineation of prognostic biomarkers in prostate cancer , 2001, Nature.

[80]  M. Billeter,et al.  Dynamics-modulated Biological Activity of Transforming Growth Factor β3* 210 , 2002, The Journal of Biological Chemistry.

[81]  J. Goldblum,et al.  PDGF-A, PDGF-Rβ, TGFβ3 and bone morphogenic protein-4 in desmoplastic small round cell tumors with EWS-WT1 gene fusion product and their role in stromal desmoplasia: an immunohistochemical study , 2005, Modern Pathology.

[82]  M. J. van de Vijver,et al.  Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. , 2006, Journal of the National Cancer Institute.

[83]  L. Wakefield,et al.  TGF-beta signaling: positive and negative effects on tumorigenesis. , 2002, Current opinion in genetics & development.

[84]  D. Lawrence.  Latent-TGF-beta: an overview. , 2001, Molecular and cellular biochemistry.

[85]  A. Balmain,et al.  Genetic events and the role of TGF beta in epithelial tumour progression. , 1999, The Journal of pathology.

[86]  Brian Bierie,et al.  Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. , 2005, Cancer research.

[87]  A. Balmain,et al.  TGF-beta signaling in tumor suppression and cancer progression. , 2001, Nature genetics.

[88]  D. L. Weeks,et al.  Epithelial-mesenchymal transformation of embryonic cardiac endothelial cells is inhibited by a modified antisense oligodeoxynucleotide to transforming growth factor beta 3. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[89]  C. Garbe,et al.  Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro. , 1994, Anticancer research.

[90]  Shiva Gautam,et al.  Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. , 2004, Cancer Research.

[91]  D. Foreman,et al.  Control of scarring in adult wounds by neutralising antibody to transforming growth factor β , 1992, The Lancet.

[92]  L. Chin,et al.  Malignant melanoma: modern black plague and genetic black box. , 1998, Genes & development.

[93]  P. Nowell,et al.  Transforming growth factor beta production and responsiveness in normal human melanocytes and melanoma cells. , 1994, Cancer research.

[94]  M. Sporn,et al.  Localization and actions of transforming growth factor-beta s in the embryonic nervous system. , 1991, Development.

[95]  Justis P. Ehlers,et al.  Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. , 2006, Cancer research.

[96]  M. Longaker,et al.  Differential Effects of TGF-&bgr;1 and TGF-&bgr;3 on Chondrogenesis in Posterofrontal Cranial Suture–Derived Mesenchymal Cells In Vitro , 2009, Plastic and reconstructive surgery.

[97]  A. Hinck,et al.  Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex. , 2002, Nature structural biology.

[98]  L. Wakefield,et al.  TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression , 2003 .

[99]  L. Wakefield,et al.  Reduction in Smad2/3 signaling enhances tumorigenesis but suppresses metastasis of breast cancer cell lines. , 2003, Cancer research.

[100]  M. Gebhardt,et al.  Expression of transforming growth factor‐β (TGF‐β) isoforms in osteosarcomas , 1997 .

[101]  R. Glynn,et al.  Epidemiologic aspects of uveal melanoma. , 1988, Survey of ophthalmology.

[102]  Fred R. Miller,et al.  Malignant MCF10CA1 Cell Lines Derived from Premalignant Human Breast Epithelial MCF10AT Cells , 2004, Breast Cancer Research and Treatment.

[103]  S. Kumar,et al.  Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. , 2000, Anticancer research.

[104]  D. Sinha,et al.  Prevention of mammary carcinogenesis in rats by pregnancy: effect of full-term and interrupted pregnancy. , 1988, British Journal of Cancer.

[105]  Gregory De Crescenzo,et al.  Three Key Residues Underlie the Differential Affinity of the TGFβ Isoforms for the TGFβ Type II Receptor , 2006 .

[106]  M. Sporn,et al.  Transforming growth factor-beta s in mammary tumorigenesis: promoters or antipromoters? , 1995, Progress in clinical and biological research.

[107]  S. Shapiro,et al.  A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. , 1994, American journal of epidemiology.

[108]  M. Sporn,et al.  Transforming growth factors. , 1985, Cancer surveys.

[109]  P. Itin,et al.  In situ analysis of transforming growth factor-βs (TGF-β1, TGF-β2, TGF-β3and TGF-3 type II receptor expression in malignant melanoma , 1995 .

[110]  D. Fisher,et al.  SKI Activates Wnt/-Catenin Signaling in Human Melanoma1 , 2003 .

[111]  M. Ferguson,et al.  Transforming growth factor-beta 3 is required for secondary palate fusion. , 1995, Nature genetics.

[112]  E. Arciniegas,et al.  Transforming growth factor-beta2 and beta3 expression in carcinoma of the prostate. , 2004, Archivos espanoles de urologia.

[113]  D. Lawrence.  Latent-TGF-β: An overview , 2001, Molecular and Cellular Biochemistry.

[114]  Pengbo Liu,et al.  Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. , 2006, Cancer research.

[115]  B. S. Lee,et al.  Human leiomyoma smooth muscle cells show increased expression of transforming growth factor-beta 3 (TGF beta 3) and altered responses to the antiproliferative effects of TGF beta. , 2001, The Journal of clinical endocrinology and metabolism.

[116]  L. Wakefield,et al.  The two faces of transforming growth factor beta in carcinogenesis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[117]  R. L. Baldwin,et al.  Altered expression of transforming growth factor‐β ligands and receptors in primary and recurrent ovarian carcinoma , 1999, Cancer.

[118]  S. Herrick,et al.  Experimental manipulation of transforming growth factor-beta isoforms significantly affects adhesion formation in a murine surgical model. , 2005, The American journal of pathology.

[119]  R. Roberts,et al.  The loss of TGF-beta signaling promotes prostate cancer metastasis. , 2003, Neoplasia.

[120]  M. Sporn,et al.  Type beta transforming growth factor: a bifunctional regulator of cellular growth. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[121]  P. Courtoy,et al.  Opposite regulation of transforming growth factors-beta2 and -beta3 expression in the human endometrium. , 2008, Endocrinology.

[122]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[123]  R. Derynck,et al.  Differential Binding of Transforming Growth Factor-β1, -β2, and -β3 by Fibroblasts and Epithelial Cells Measured by Affinity Cross-Linking of Cell Surface Receptors , 1991 .

[124]  A. Bassols,et al.  The effect of TGF-beta 1 on cell proliferation and proteoglycan production in human melanoma cells depends on the degree of cell differentiation. , 1996, Cancer letters.

[125]  H. Adami,et al.  Parity, age at first and last birth, and risk of breast cancer: A population-based study in Sweden , 2005, Breast Cancer Research and Treatment.

[126]  A. Hinck,et al.  Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor. , 2006, Journal of molecular biology.

[127]  D. Schadendorf,et al.  Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. , 2006, Pigment cell research.

[128]  Hiroki Nagase,et al.  Genetic architecture of murine skin inflammation and tumor susceptibility , 2016 .

[129]  L. Wakefield,et al.  The two faces of transforming growth factor β in carcinogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[130]  A. Roberts,et al.  Bidirectional effects of transforming growth factor beta (TGF-beta) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF-beta isoforms. , 1991, Blood.

[131]  R. Hong,et al.  Relation between histological intensity of transforming growth factor-beta isoforms in human osteosarcoma and the rate of lung metastasis. , 1998, The Tohoku journal of experimental medicine.

[132]  D. Warburton,et al.  Progressive pulmonary fibrosis is mediated by TGF-β isoform 1 but not TGF-β3 , 2008 .

[133]  S. O'Kane,et al.  Scar-free healing: from embryonic mechanisms to adult therapeutic intervention. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[134]  M. Grütter,et al.  The crystal structure of TGF‐β3 and comparison to TGF‐β2: Implications for receptor binding , 1996, Protein science : a publication of the Protein Society.

[135]  R. W. Padgett.  TGFbeta signaling pathways and human diseases. , 1999, Cancer metastasis reviews.

[136]  R. Markwald,et al.  Expression of smooth muscle alpha‐actin in mesenchymal cells during formation of avian endocardial cushion tissue: A role for transforming growth factor β3 , 1997, Developmental dynamics : an official publication of the American Association of Anatomists.

[137]  G. Boivin,et al.  TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. , 1997, Development.

[138]  S. Kumar,et al.  Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer. , 1998, International journal of cancer.

[139]  J. Keski‐Oja,et al.  Latency, activation, and binding proteins of TGF‐β , 2001, Microscopy research and technique.

[140]  M. Gebhardt,et al.  Expression of transforming growth factor-beta (TGF-beta) isoforms in osteosarcomas: TGF-beta3 is related to disease progression. , 1997, Cancer.

[141]  J. Massagué,et al.  Betaglycan presents ligand to the TGFβ signaling receptor , 1993, Cell.

[142]  J. Bergh,et al.  Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series , 2007, Clinical Cancer Research.

[143]  R. Derynck,et al.  Differential binding of transforming growth factor-beta 1, -beta 2, and -beta 3 by fibroblasts and epithelial cells measured by affinity cross-linking of cell surface receptors. , 1991, Molecular endocrinology.

[144]  D. Rifkin,et al.  Making sense of latent TGFbeta activation. , 2003, Journal of cell science.

[145]  L. Wakefield,et al.  Synthesis and secretion of transforming growth factor beta isoforms by primary cultures of human breast tumour fibroblasts in vitro and their modulation by tamoxifen. , 1996, British Journal of Cancer.

[146]  K. Flanders,et al.  Differential effects of transforming growth factor-βs and glial cell line-derived neurotrophic factor on gene expression of presenilin-1 in human post-mitotic neurons and astrocytes , 1999, Neuroscience.

[147]  J. Russo,et al.  Differentiation of the mammary gland and susceptibility to carcinogenesis , 2005, Breast Cancer Research and Treatment.

[148]  A. Albino,et al.  Induction of growth factor RNA expression in human malignant melanoma: markers of transformation. , 1991, Cancer research.

[149]  C. Potten,et al.  Protection against mucosal injury by growth factors and cytokines. , 2001, Journal of the National Cancer Institute. Monographs.

[150]  Adam S. Kibel,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007 .

[151]  L. Chodosh,et al.  Persistent parity-induced changes in growth factors, TGF-beta3, and differentiation in the rodent mammary gland. , 2002, Molecular endocrinology.

[152]  F. Miller,et al.  MCF10AT: a model for the evolution of cancer from proliferative breast disease. , 1996, The American journal of pathology.

[153]  A. Kulkarni,et al.  Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. , 1995, Development.

[154]  L. Tay,et al.  7,12-dimethylbenz[a]anthracene-induced DNA binding and repair synthesis in susceptible and nonsusceptible mammary epithelial cells in culture. , 1981, Journal of the National Cancer Institute.

[155]  A. Tsamandas,et al.  TGFβ1, TGFβ2, and TGFβ3 Protein Expression in Gastric Carcinomas: Correlation with Prognostics Factors and Patient Survival , 2007 .

[156]  L. Hefler,et al.  Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast. , 2004, The International journal of biological markers.

[157]  J. Trent,et al.  Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis , 2002, The Prostate.

[158]  D. Foreman,et al.  Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. , 1994, Journal of cell science.

[159]  Carlos L Arteaga,et al.  Transforming growth factor-β and breast cancer: Tumor promoting effects of transforming growth factor-β , 2000, Breast Cancer Research.

[160]  J. Chirgwin,et al.  Transforming Growth Factor-Stimulates Parathyroid Hormone-related Protein and Osteolytic Metastases via Smad and Mitogen-activated Protein Kinase Signaling Pathways * , 2002 .

[161]  R. Derynck,et al.  TGF-beta signaling in cancer--a double-edged sword. , 2001, Trends in cell biology.

[162]  P. Itin,et al.  In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma. , 1995, Carcinogenesis.

[163]  P S Gartside,et al.  Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. , 1999, Cancer research.

[164]  U. Rodeck,et al.  Differential expression of transforming growth factors-β1, -β2 and -β3 in human colon carcinoma , 2001 .

[165]  A. Green,et al.  Expression and secretion of TGF-beta isoforms and expression of TGF-beta-receptors I, II and III in normal and neoplastic human breast. , 1999, International journal of oncology.

[166]  M. Ferguson,et al.  Transforming growth factor–β3 is required for secondary palate fusion , 1995, Nature Genetics.

[167]  L. DiPietro,et al.  Site‐specific production of TGF‐β in oral mucosal and cutaneous wounds , 2008 .

[168]  S. Nandi,et al.  Protective effects of pregnancy and lactation against N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats. , 1999, Carcinogenesis.

[169]  L. Lund,et al.  Laser capture microdissection-based in vivo genomic profiling of wound keratinocytes identifies similarities and differences to squamous cell carcinoma , 2003, Oncogene.

[170]  D. Spandidos,et al.  Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis. , 2006, Cancer letters.

[171]  M. Sporn,et al.  Suppression of carcinogenesis: a role for TGF-beta and related molecules in prevention of cancer. , 1990, Immunology series.

[172]  Martin F. Mihm,et al.  Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[174]  H. Chien,et al.  Expression of TGF-beta isoforms and their receptors during mineralized nodule formation by rat periodontal ligament cells in vitro. , 1999, Journal of periodontal research.

[175]  K. Jöckel,et al.  Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. , 2003, Cancer research.

[176]  P. Musiani,et al.  Carcinomas in Transgenic BALB / c Mice Carcinogenesis Than Transplantable p 185 More Effectively Inhibits DNA Vaccination Against Rat Her-2 / Neu Musiani and , 2000 .

[177]  L. DiPietro,et al.  Site-specific production of TGF-beta in oral mucosal and cutaneous wounds. , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[178]  Van,et al.  A gene-expression signature as a predictor of survival in breast cancer. , 2002, The New England journal of medicine.

[179]  G. Gurtner.  Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies , 2010 .

[180]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[181]  L. Wakefield,et al.  TGF-β signaling: positive and negative effects on tumorigenesis , 2002 .

[182]  J L Kelsey,et al.  Reproductive factors and breast cancer. , 1993, Epidemiologic reviews.

[183]  L. Tay,et al.  Formation and removal of 7,12-dimethylbenz[a]anthracene--nucleic acid adducts in rat mammary epithelial cells with different susceptibility to carcinogenesis. , 1981, Carcinogenesis.